NICE OK’s restricted use of Bayer’s prostate cancer drug
The National Institute for Health and Care Excellence will issue a Final Appraisal Determination recommending Bayer’s Xofigo for National Health Service use to treat certain patients with prostate cancer, but only in the post-chemo setting.
The cost regulator has ruled that Xofigo (Radium-223 dichloride) should be considered an option for treating adults with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy. Read more.
Tags: Cancer Marketplace Prostate